Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Grants Stock Options

GlobeNewswire March 27, 2019

IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results

GlobeNewswire March 22, 2019

IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow

GlobeNewswire March 18, 2019

IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site

GlobeNewswire February 14, 2019

IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™

GlobeNewswire February 11, 2019

IntelGenx Strengthens Senior Management Team

GlobeNewswire February 7, 2019

IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA

GlobeNewswire January 30, 2019

IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial

GlobeNewswire January 23, 2019

IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act

GlobeNewswire January 14, 2019

IntelGenx Grants Restricted Share Units

GlobeNewswire December 26, 2018

IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States

GlobeNewswire December 12, 2018

IntelGenx Reports Amendment of Stock Option Plan

GlobeNewswire December 5, 2018

IntelGenx Engages Focus Communications for Investor Relations Program

GlobeNewswire November 30, 2018

IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study

GlobeNewswire November 27, 2018

IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®

GlobeNewswire November 20, 2018

IntelGenx Closes Private Placement Financing

GlobeNewswire November 13, 2018

Various Technological Advancements are set to Grow the Global Biotechnology Market

PR Newswire November 9, 2018

IntelGenx Reports Third Quarter 2018 Financial Results

GlobeNewswire November 8, 2018

IntelGenx Announces Definitive Agreement with Tilray® to Form an Exclusive, Worldwide Partnership for Cannabis-Infused VersaFilm™ Products

GlobeNewswire November 7, 2018

IntelGenx to Report Third Quarter 2018 Financial Results on November 8, 2018 – Conference Call to Follow

GlobeNewswire November 1, 2018